Event Details

AD/PD™ 2022 attracts international medical and scientific professionals worldwide. The Conference is at the forefront of unraveling the mechanisms and improving the treatment of Alzheimer’s, Parkinson’s, and other related neurodegenerative diseases. AD/PD™ Conferences uniquely combine distinct neurodegenerative diseases in one setting and examine their similarities and differences; a strong focus is mechanisms of disease, prevention, and therapy.

Cognition will be presenting results from the clinical development program of CT1812, a small-molecule sigma-2 (σ-2) receptor modulator in development for age-related neurodegenerative disorders: 

• Poster (P232): Experimental Therapeutic CT1812 Demonstrates Target Engagement in a Phase 1b Clinical Trial in Alzheimer's Patients to Measure Displacement of Abeta Oligomers into CSF
• Poster (P233): Proteomic Analysis of CSF in a Phase 2 Clinical Trial in Alzheimer's Patients to Identify Pharmacodynamic Biomarkers of the S2R Modulator, CT1812